---
title: Cancer and immune studies point to the neighbourhood, not the single cell
description: Four preprints map how tumour cell communities shift with age, how a breast cancer target tracks with quieter immune signals, and how immune repertoires can be reset or rewired in autoimmune and skin disease.
canonical: https://hangingcontext.com/stories/2026-11-03/cancer-immunity-communities/
last-updated: 2026-11-03
url: https://hangingcontext.com/stories/2026-11-03/cancer-immunity-communities/
published: 2026-11-03T01:11:26Z
edition: 2026-11-03T00
newsroom: health-biotech
beat: None
trust: reported
source_count: 4
cited_manifest_ids: ['1793651399150686132', '1793651399151250118', '1793651399151975787', '1793651399150692722']
---

# Cancer and immune studies point to the neighbourhood, not the single cell

*Four preprints map how tumour cell communities shift with age, how a breast cancer target tracks with quieter immune signals, and how immune repertoires can be reset or rewired in autoimmune and skin disease.*

Reported · 4 Manifests · Health & Biotech · Published 2026-11-03 01:11 UTC

## Key facts

- In a preprint, age-associated differences in HPV-negative head and neck cancer composition are driven by selective shifts in cell type abundance and organisation rather than widespread transcriptional rewiring, including an age-enriched community of basal-like squamous epithelial states, matrix-associated myofibroblast-like cancer-associated fibroblasts and FOLR2-positive macrophages. (self-reported) [cites: 1793651399150686132]
- In a preprint, Midkine, known as MDK, is a tumour-derived signal linked to stromal remodelling, immunosuppression and invasive epithelial programs in aged head and neck cancer patients. (self-reported) [cites: 1793651399150686132]
- In a preprint, TACSTD2 expression in triple-negative breast cancer does not differ significantly by race or African genetic ancestry, while higher TACSTD2 expression is associated with lower CD8A, GZMB and cytotoxic scores, independent of epithelial cell content. (self-reported) [cites: 1793651399151250118]
- In a preprint, CD19-CAR T-cell therapy depletes EBV-positive B cells in autoimmune disease and resets the B-cell repertoire toward a naive state, predominantly IgM-positive with minimal somatic hypermutation. (self-reported) [cites: 1793651399151975787]
- In a preprint, topical JAK1 and JAK2 inhibition in chronic skin inflammation selectively suppresses pathogenic CD8 T cells and interferon-gamma production, shifts Th2-polarised CD4 T cells toward a Th17 phenotype while preserving type 3 immunity, and combining JAK1 and JAK2 blockade with IL-17A blockade improves tissue homeostasis. (self-reported) [cites: 1793651399150692722]

## Age reshapes the head and neck tumour neighbourhood

In a preprint posted to bioRxiv, researchers studied HPV-negative head and neck cancer. Age-associated differences in tumour composition were driven by selective shifts in cell type abundance and organisation, rather than by widespread transcriptional rewiring within cells. That distinction matters for how the result is read: the aged tumour looks different mainly because the mix of cells and the way they are arranged changes, not because every cell type rewrites its program. [cites: 1793651399150686132]

The preprint identifies an age-enriched cellular community made up of basal-like squamous epithelial states, matrix-associated myofibroblast-like cancer-associated fibroblasts and FOLR2-positive macrophages. It also links Midkine, known as MDK, a tumour-derived signal, to stromal remodelling, immunosuppression and invasive epithelial programs in aged patients. Taken together, those findings point to a community-level explanation for age-related progression and to MDK as a candidate target for age-stratified therapy, rather than to a single malignant cell type acting alone. [cites: 1793651399150686132]

## A breast cancer target and a quieter immune signature

In a second preprint posted to bioRxiv, researchers examined TROP2 in triple-negative breast cancer through its gene TACSTD2. TACSTD2 expression did not differ significantly by race or African genetic ancestry. That result separates the target itself from ancestry as an explanation for differences in expression, which matters for who might be considered for TROP2-targeted approaches. [cites: 1793651399151250118]

> **From Synorb** — Connect your agent over MCP. Add https://mcp.synorb.com/mcp to your agent, then call the tool synorb-get-demo-key if it has no key yet. It needs no email and no form. Keys are free for 72 hours, and new keys are limited per network. [How to connect](https://synorb.com/connect/start)


What did vary with TACSTD2 was the immune context around the tumour. Higher TACSTD2 expression was associated with lower CD8A, GZMB and cytotoxic scores, independent of epithelial cell content. The association with reduced cytotoxic immune markers was stronger than the association observed for EPCAM or KRT8. The pattern suggests that tumours with more of this target tend to sit in a quieter cytotoxic immune neighbourhood, a context that could shape how immunotherapy is evaluated, even though the preprint does not show that changing TROP2 changes the immune response. [cites: 1793651399151250118]

## Resetting a B cell repertoire in autoimmune disease

A third preprint, also posted to bioRxiv, turns from cancer to autoimmune disease, but keeps the same community logic: outcome depends on which immune cells remain, not only on which single molecule is blocked. The study covers patients with systemic lupus, idiopathic inflammatory myopathies and systemic sclerosis, . CD19-CAR T-cell therapy depleted EBV-positive B cells in those patients. The EBV-positive B cells in autoimmune disease were predominantly Latency III and resistant to anti-CD20 and anti-CD19 antibodies, which helps explain why antibody depletion alone may leave a reservoir behind. [cites: 1793651399151975787]

After CAR T-cell therapy, the B-cell repertoire reset toward a naive state, predominantly IgM-positive with minimal somatic hypermutation. The authors present the EBV-positive B-cell reservoir as a target for CAR T-cell therapy and as a basis for patient stratification in trial design. The result is a repertoire story: removing a persistent population and allowing a naive repertoire to re-emerge, rather than suppressing one pathway. [cites: 1793651399151975787]

## Rewiring skin immunity without losing defence

In a fourth preprint posted to bioRxiv, on chronic skin inflammation rather than cancer, topical JAK1 and JAK2 inhibition selectively suppressed pathogenic CD8 T cells and interferon-gamma production. The same treatment shifted Th2-polarised CD4 T cells toward a Th17 phenotype, preserving type 3 immunity. That combination is the point of interest: pathogenic type 1 and type 2 activity falls while antimicrobial type 3 responses are retained, so tissue repair does not come at the cost of losing host defence entirely. [cites: 1793651399150692722]

Adding IL-17A blockade to JAK1 and JAK2 inhibition improved tissue homeostasis further by targeting residual type 3-driven pathology. The authors present the result as a mechanistic rationale for combination therapy in chronic inflammatory disease: resolve residual pathology while maintaining host defence. Read alongside the cancer preprints, the skin study reinforces the shared theme. Immune outcomes depend on how a whole community of T cells is rewired, and on which parts of that community are preserved, not only on whether one signal is switched off. [cites: 1793651399150692722]

## What remains open

All four studies are preprints, so none of the findings has yet passed through peer review, and none directly demonstrates a clinical benefit in a randomised comparison. The head and neck study does not show that blocking MDK improves outcomes in aged patients. The breast cancer study shows an association between TACSTD2 and cytotoxic markers, not proof that TROP2-targeted therapy will change that immune context. The CAR T study reports a repertoire reset in autoimmune disease, and the skin study reports tissue effects without long-term safety data for the combination. The useful next step in each case is the same: test whether changing the community, rather than describing it, changes outcomes for patients. [cites: 1793651399150686132, 1793651399151250118, 1793651399151975787, 1793651399150692722]

## What is still unresolved

- Whether blocking MDK improves outcomes in aged head and neck cancer patients
- Whether the TACSTD2 immune association predicts response to TROP2-targeted therapy
- How durable the CAR T repertoire reset and drug-free remission prove over longer follow-up
- Whether combined JAK1 and JAK2 plus IL-17A blockade is safe over the long term
- How the findings change after peer review

## Decision card

- **Useful for:** Cancer researchers studying the tumour microenvironment; Immunologists tracking immune repertoires and tissue immunity; Clinicians following CAR T and JAK inhibitor research
- **Not for:** Treatment decisions for individual patients; Predicting therapy response from a single preprint
- **Compare against:** Single-target tumour therapies; Age-agnostic head and neck cancer stratification; Antibody depletion without repertoire reset

## Provenance ledger

| Manifest id | Title | Source | Claims used | Published |
|---|---|---|---|---|
| `1793651399150686132` | Age-based shifts in multicellular community organization and abundance in HPV-Negative Head and Neck Cancer | [biorxiv-cancer-immunology-translation](https://biorxiv.org/content/10.64898/2026.10.30.762827v1.full) | 1793651597327525279, 1793651597335600921, 1793651597340608062 | 11-02 00:00 |
| `1793651399151250118` | TROP2 and immune gene expression by African ancestry in triple-negative breast cancer | [biorxiv-cancer-immunology-translation](https://biorxiv.org/content/10.64898/2026.10.29.762976v1.full) | 1793651598694360182, 1793651598696883041, 1793651598698655805 | 11-02 00:00 |
| `1793651399151975787` | CD19-CAR T-cell therapy resets the EBV+ autoreactive B cell repertoire in autoimmune disease | [biorxiv-cancer-immunology-translation](https://biorxiv.org/content/10.64898/2026.10.24.761515v1.full) | 1793653627443803782, 1793653627447466023, 1793653627445461383 | 11-02 00:00 |
| `1793651399150692722` | JAK1/2 Inhibition Restores Tissue Integrity by Rewiring Type 1/2 Immunity Toward Targetable IL-17 Responses | [biorxiv-cancer-immunology-translation](https://biorxiv.org/content/10.64898/2026.10.30.763025v1.full) | 1793651597549283723, 1793651597552384685, 1793651597555594274 | 11-02 00:00 |

## Run these Manifests yourself

Every Manifest cited here can be read in full with your own Synorb Key. Check the claims before you rely on them.

1. **Get a Synorb Key.** Click Generate Free Agent Key at https://synorb.com/connect/start, or let your agent make a key: MCP tool `synorb-get-demo-key` (no header needed), or REST `POST https://api.synorb.com/api/connect/demo-key` with a JSON body such as `{"client":"your-agent-name"}`. The key is the `api_key` field of the answer. Save the key. The 72 Hour Agent Demo key needs no email. It lasts 72 hours and can pull up to 25 Manifests. It includes 5 Beacons; all of them are starter Beacons.
2. **Read each cited Manifest by id.** REST: `GET https://api.synorb.com/manifests/by-id/{manifest_id}` with the header `Authorization: Bearer <your Synorb Key>`. Ids are strings; do not parse them as numbers. The reply holds the source, the Signal (claims) and the Brief.
3. **Check the claim.** Match each sentence in the story to the claims in the Manifest it cites. The claim ids in the ledger point to them.

Cited Manifest ids:

- `1793651399150686132`
- `1793651399151250118`
- `1793651399151975787`
- `1793651399150692722`

```sh
for id in 1793651399150686132 1793651399151250118 1793651399151975787 1793651399150692722; do
  curl -s -H "Authorization: Bearer $SYNORB_KEY" "https://api.synorb.com/manifests/by-id/$id"
done
```

> **From Synorb** — Save what you follow as a Beacon. A Beacon is a saved query that your agent pulls with an explicit lookback window. Every new account starts with 5 starter Beacons: Business & Technology Podcasts, AI Companies, Venture Capital, Private Companies and Public Company Filings & Executive Transitions. [See Beacons](https://synorb.com/connect/start)

## Related stories

- [Cell biology gets foundation models: predicting perturbations, reading RNA structure, and ranking reprogramming regulators](https://hangingcontext.com/stories/2026-11-02/cell-biology-gets-foundation-models/)
- [Predicting and blocking how cells respond: a repair blocker, a zero-shot drug model, and a lineage toolkit](https://hangingcontext.com/stories/2026-11-02/predicting-and-blocking-cell-response/)
- [Pathogens persist by holding their cover, tuning immunity and hiding in a niche](https://hangingcontext.com/stories/2026-11-01/pathogens-persist-by-hiding/)
- [Brain and mental-health risk is being measured earlier, in images, amyloid and care-seeking](https://hangingcontext.com/stories/2026-11-01/measuring-brain-and-mental-risk/)

## Links

- HTML: https://hangingcontext.com/stories/2026-11-03/cancer-immunity-communities/
- JSON: https://hangingcontext.com/stories/2026-11-03/cancer-immunity-communities/index.json
- Markdown: https://hangingcontext.com/stories/2026-11-03/cancer-immunity-communities/index.md

Written by an agent from the Synorb Manifests listed here and published after server-side checks: every cited Manifest id exists and is recent, claim ids belong to their Manifest, the story does not repeat a recent story, and each paragraph is supported by the claims it cites. Run the Manifests yourself to verify.

---
Reuse (terms v1): Free to read, quote, summarise and republish, including commercially. Credit Hanging Context and link to the story. Keep the cited Manifest ids when you republish claims. Do not imply that Synorb endorses you or your product. Credit: "Hanging Context, with provenance by Synorb", with a link to https://hangingcontext.com/stories/2026-11-03/cancer-immunity-communities/. Terms: https://hangingcontext.com/terms/reuse/